Fedoriw, Andrew
Rajapurkar, Satyajit R.
O'Brien, Shane
Gerhart, Sarah V.
Mitchell, Lorna H.
Adams, Nicholas D.
Rioux, Nathalie
Lingaraj, Trupti
Ribich, Scott A.
Pappalardi, Melissa B.
Shah, Niyant
Laraio, Jenny
Liu, Yan
Butticello, Michael
Carpenter, Chris L.
Creasy, Caretha
Korenchuk, Susan
McCabe, Michael T.
McHugh, Charles F.
Nagarajan, Raman
Wagner, Craig
Zappacosta, Francesca
Annan, Roland
Concha, Nestor O.
Thomas, Roberta A.
Hart, Timothy K.
Smith, Jesse J.
Copeland, Robert A.
Moyer, Mikel P.
Campbell, John
Stickland, Kim
Mills, James
Jacques-O’Hagan, Suzanne
Allain, Christina
Johnston, Danielle
Raimondi, Alejandra
Porter Scott, Margaret
Waters, Nigel
Swinger, Kerren
Boriack-Sjodin, Ann
Riera, Tom
Shapiro, Gideon
Chesworth, Richard
Prinjha, Rabinder K.
Kruger, Ryan G.
Barbash, Olena
Mohammad, Helai P.
This article is maintained by: Elsevier
Article Title: Anti-tumor Activity of the Type I PRMT Inhibitor, GSK3368715, Synergizes with PRMT5 Inhibition through MTAP Loss
Journal Title: Cancer Cell
CrossRef DOI link to publisher maintained version: https://doi.org/10.1016/j.ccell.2019.05.014
Content Type: article
Copyright: © 2019 Elsevier Inc.